Basal insulin supplementation in Type 1 diabetic children: A long-term comparative observational study between continuous subcutaneous insulin infusion and glargine insulin

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Journal of Endocrinological Investigation

• Publication date

  2007-07-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1007/BF03346351PMID 17848840
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Insulin Glargine

  2012cited by this paper
• Insulin pump use in young adolescents with type 1 diabetes: a descriptive study

  2005cited by this paper
• Continuous subcutaneous insulin infusion in toddlers and children with type 1 diabetes mellitus is safe and effective

  2005cited by this paper
• An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes

  2005cited by this paper
• A randomized controlled trial of insulin pump therapy in young children with type 1 diabetes.

  2005cited by this paper
• Optimization of basal insulin delivery in Type 1 diabetes: a retrospective study on the use of continuous subcutaneous insulin infusion and insulin glargine

  2005cited by this paper
• A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine.

  2004cited by this paper
• A comparison of basal insulin delivery: continuous subcutaneous insulin infusion versus glargine.

  2003cited by this paper
• Randomized cross-over trial of insulin glargine plus lispro or NPH insulin plus regular human insulin in adolescents with type 1 diabetes on intensive insulin regimens.

  2003cited by this paper
• A randomized clinical trial comparing breakfast, dinner, or bedtime administration of insulin glargine in patients with type 1 diabetes.

  2003cited by this paper
• Biotransformation of insulin glargine after subcutaneous injection in healthy subjects

  2003cited by this paper
• Follow-up report on the diagnosis of diabetes mellitus.

  2003cited by this paper
• Continuous subcutaneous insulin infusion and multiple daily injection therapy are equally effective in type 2 diabetes: a randomized, parallel-group, 24-week study.

  2003cited by this paper
• Effect of Therapy with Insulin Glargine (Lantus®) on Glycemic Control in Toddlers, Children, and Adolescents with Diabetes

  2003cited by this paper
• Both continuous subcutaneous insulin infusion and a multiple daily insulin injection regimen with glargine as basal insulin are equally better than traditional multiple daily insulin injection treatment.

  2003cited by this paper
• Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised controlled trials

  2002cited by this paper
• To pump or not to pump.

  2002cited by this paper
• Insulin glargine: a new long-acting insulin product.

  2002cited by this paper
• Continuous subcutaneous insulin infusion at 25 years: evidence base for the expanding use of insulin pump therapy in type 1 diabetes.

  2002cited by this paper
• Comparative Trial Between Insulin Glargine and NPH Insulin in Children and Adolescents with Type I Diabetes Mellitus

  2002cited by this paper
• Insulin pump therapy in pediatrics: a therapeutic alternative to safely lower HbA1c levels across all age groups

  2002cited by this paper
• Basal Insulin Glargine (HOE 901) versus NPH Insulin in Patients With Type 1 Diabetes on Multiple Daily Insulin Regimes

  2001cited by this paper
• Intensive insulin treatment in diabetic children.

  2001cited by this paper
• Physiological insulin replacement in type 1 diabetes mellitus.

  2001cited by this paper
• Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. U.S. Insulin Glargine (HOE 901) Type 1 Diabetes Investigator Group.

  2000cited by this paper
• Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro.

  2000cited by this paper
• Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. U.S. Study Group of Insulin Glargine in Type 1 Diabetes.

  2000cited by this paper
• Comparison of continuous subcutaneous insulin infusion and multiple daily injection regimens using insulin lispro in type 1 diabetic patients on intensified treatment: a randomized study. The Study Group for the Development of Pump Therapy in Diabetes.

  2000cited by this paper
• Adverse events in intensively treated children and adolescents with type 1 diabetes

  1999cited by this paper
• Report of the expert committee on the diagnosis and classification of diabetes mellitus.

  1999cited by this paper
• Substitution of night-time continuous subcutaneous insulin infusion therapy for bedtime NPH insulin in a multiple injection regimen improves counterregulatory hormonal responses and warning symptoms of hypoglycaemia in IDDM

  1998cited by this paper
• Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus

  1997cited by this paper
• Insulin formulation and delivery.

  1997cited by this paper
• The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

  1993cited by this paper
• Insulin Pharmacokinetics

  1984cited by this paper
• Intensified Insulin Therapy in the Type I Diabetic Adolescent: A Controlled Trial

  1984cited by this paper

• Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents

  2024cites this paper
• ISPAD Clinical Practice Consensus Guidelines 2022: Diabetes technologies: Insulin delivery

  2022cites this paper
• Diagnosis, Therapy and Follow-Up of Diabetes Mellitus in Children and Adolescents.

  2022cites this paper
• Real-World Application of Insulin Pump Therapy Among Patients With Type 1 Diabetes in China: A Cross-Sectional Study

  2022cites this paper
• Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter

  2021cites this paper
• Insulin Pump Therapy.

  2019cites this paper
• Diagnosis, Therapy and Follow-up of Diabetes Mellitus in Children and Adolescents.

  2019cites this paper
• Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter

  2018cites this paper
• Effectiveness of Continuous Subcutaneous Insulin Infusion on Parental Quality of Life and Glycemic Control Among Children With T1D: Meta‐Analysis

  2018influential citation
• ISPAD Clinical Practice Consensus Guidelines 2018: Diabetes technologies

  2018cites this paper
• 20 Years of insulin lispro in pediatric type 1 diabetes: a review of available evidence

  2017cites this paper
• The rise of technology in diabetes care. Not all that is new is necessarily better

  2016cites this paper
• Comparative Effectiveness and Safety of Methods of Insulin Delivery and Glucose Monitoring for Diabetes Mellitus

  2012influential citation
• Methods for Insulin Delivery and Glucose Monitoring in Diabetes: Summary of a Comparative Effectiveness Review

  2012cites this paper
• Methods for Insulin Delivery and Glucose Monitoring: Comparative Effectiveness

  2012influential citation
• Diagnostik, Therapie und Verlaufskontrolle des Diabetes mellitus im Kindes- und Jugendalter

  2012cites this paper
• Continuous subcutaneous infusion of insulin lispro in children and adolescents with type 1 diabetes mellitus.

  2012cites this paper
• Glargine basal-bolus insulin regimen versus insulin pump therapy: comparison of glycemic control

  2011cites this paper
• Estudio longitudinal del impacto del tratamiento con infusores de insulina en variables psicológicas, la calidad de vida el control glucémico de pacientes con diabetes mellitus tipo 1

  2010cites this paper
• Treatment options for paediatric diabetes

  2010influential citation
• Biphasic insulin aspart 30/70 (BIAsp 30) in the treatment of type 1 and type 2 diabetes

  2009cites this paper
• Continuous subcutaneous insulin infusion (CSII) 30 years later: still the best option for insulin therapy

  2009cites this paper
• Reducing postprandial hyperglycemia with adjuvant premeal pramlintide and postmeal insulin in children with type 1 diabetes mellitus

  2009cites this paper
• Biphasic insulin aspart 30/70 (BiAsp 30) in the treatment of type 1 and type 2 diabetes

  2009cites this paper
• Effects of insulin therapy with continuous subcutaneous insulin infusion (CSII) in diabetic patients: comparison with multi-daily insulin injections therapy (MDI).

  2009cites this paper
• From pumps to prevention: recent advances in the treatment of type 1 diabetes.

  2009cites this paper
• Past, present, and future of insulin pump therapy: better shot at diabetes control.

  2008cites this paper